Welcome to our dedicated page for Lantheus Holding news (Ticker: LNTH), a resource for investors and traders seeking the latest updates and insights on Lantheus Holding stock.
Lantheus Holdings, Inc. (NASDAQ: LNTH) is a global leader in radiopharmaceuticals and diagnostic imaging solutions, pioneering innovations in cardiovascular, oncology, and neurology diagnostics. This dedicated news hub provides investors and healthcare professionals with timely updates on the company’s strategic developments, financial performance, and clinical advancements.
Access authoritative coverage of LNTH’s earnings reports, regulatory milestones, and product launches. Our curated collection includes press releases on new imaging agents, partnership announcements with leading medical institutions, and updates on clinical trial progress. Discover how Lantheus’ precision diagnostics and radiopharmaceutical oncology solutions continue to shape modern medical imaging.
Key updates cover FDA approvals, international expansion efforts, and technological collaborations enhancing nuclear medicine capabilities. Bookmark this page for streamlined access to essential information about LNTH’s role in advancing diagnostic accuracy and therapeutic monitoring across global healthcare systems.
Lantheus Holdings reported Q4 2020 revenue of $94.2 million, an increase of 5.4% year-over-year, despite a full-year revenue decline of 2.3% to $339.4 million. The company faced a net loss of $3.4 million in Q4, down from a $10.5 million profit in Q4 2019. Adjusted EPS fell by 79.9% year-over-year to $0.07. The company expects Q1 2021 revenue between $85 million and $89 million and full-year guidance of $385 million to $400 million. Lantheus emphasizes ongoing growth and development following strategic acquisitions and FDA approvals in 2020.
Lantheus Holdings, (NASDAQ: LNTH), a leader in innovative imaging diagnostics and therapeutics, announced that Mary Anne Heino, President and CEO, along with Bob Marshall, CFO, will present at the 10th Annual SVB Leerink Global Healthcare Conference on February 26 at 3:00 p.m. ET. The live webcast can be accessed on Lantheus's website, with a replay available for 30 days. Lantheus offers a wide range of products, including DEFINITY® and TechneLite®, and operates globally with headquarters in North Billerica, Massachusetts.
Lantheus Holdings, Inc. (NASDAQ: LNTH) will host a conference call on February 25, 2021, at 4:30 p.m. ET to discuss its financial results for Q4 and the full year of 2020. The call can be accessed via telephone or through a live webcast at their website. Lantheus is recognized for its innovative imaging diagnostics and therapeutic solutions, offering products like DEFINITY®, TechneLite®, AZEDRA®, and RELISTOR®, aimed at serious medical conditions.
Lantheus Holdings, Inc. (NASDAQ: LNTH) announced that three abstracts related to its PSMA-targeted product candidates will be presented at the 2021 ASCO GU Virtual Meeting on February 11-13, 2021. These include two studies on PyL™, a PET/CT imaging agent for prostate cancer, and one on 1095, a radiopharmaceutical for metastatic castration-resistant prostate cancer. The studies focus on the efficacy and safety of these agents, showcasing Lantheus's commitment to advancing prostate cancer diagnostics and therapeutics.
Lantheus Holdings (NASDAQ: LNTH) announced the filing of a Drug Master File (DMF) with the FDA for NM-01, a PD-L1 imaging biomarker aimed at enhancing immuno-oncology clinical trials beginning in 2021. NM-01 is a proprietary radiopharmaceutical that detects PD-L1 expression in tumors, potentially improving patient evaluation for I/O therapies. The checkpoint inhibitor market, projected to grow from $25B in 2019 to $68B by 2026, highlights the relevance of this innovation. Lantheus licensed NM-01 from NanoMab Technology Limited and plans to support its use in clinical research.
Lantheus Holdings, Inc. (NASDAQ: LNTH) announced that the FDA has accepted the New Drug Application (NDA) for PyL™, a PSMA-targeted PET imaging agent for prostate cancer, granting it Priority Review. The PDUFA action date is set for May 28, 2021. The NDA is supported by data from pivotal studies OSPREY and CONDOR, showing significant improvements in diagnostic performance. Approximately 3,500 subjects have received PyL, which exhibits a favorable safety profile. The company aims to address the unmet need for reliable imaging in prostate cancer management.
Lantheus Holdings, Inc. (NASDAQ: LNTH) announced a strategic collaboration with POINT Biopharma, Inc. to advance cancer precision medicine. They will utilize Lantheus’ investigational PSMA-targeted PET imaging agent, PyL, in POINT's Phase 3 trial for metastatic castration-resistant prostate cancer (mCRPC). This partnership aims to enhance patient selection for therapy with POINT’s radioligand, 177Lu-PNT2002. Progenics Pharmaceuticals, a Lantheus subsidiary, will supply PyL at a predetermined price, underscoring the potential of combining diagnostics with therapy in cancer treatment.
Lantheus Holdings (NASDAQ: LNTH) announced a stock purchase agreement to sell its Puerto Rico radiopharmacy and PET manufacturing facility to PharmaLogic Holdings Corp for $18 million. This deal includes a long-term supply agreement, ensuring Lantheus continues supplying its nuclear medicine products in Puerto Rico. The transaction aims to streamline Lantheus' distribution model in the region and reinvest proceeds into its core businesses and product pipeline. The closing is expected in early Q1 2021, pending customary conditions.
Lantheus Holdings, Inc. (NASDAQ: LNTH) announced that CFO Bob Marshall will present at the 2020 Evercore ISI HealthCONx Conference on December 1 at 3:30 p.m. ET. The event will be accessible via a live webcast on the Company’s website, with a replay available for 30 days post-presentation. Lantheus is a leader in diagnostic and therapeutic agents, offering products like DEFINITY®, TechneLite®, AZEDRA®, and RELISTOR®. The Company is headquartered in North Billerica, Massachusetts, with additional offices across North America and Europe.
Lantheus Holdings, Inc. (NASDAQ: LNTH) has received FDA approval for its new product, DEFINITY Room Temperature (RT), a room-temperature stable formulation of the existing DEFINITY echocardiography agent. This innovation enhances portability for healthcare providers and addresses a growing need in imaging services. DEFINITY RT, activated using the VIALMIX RFID device, is expected to broaden its clinical use. The composition patent for DEFINITY RT expires in 2035, allowing for significant market presence. Lantheus aims to leverage its microbubble franchise for improved cardiac imaging.
FAQ
What is the current stock price of Lantheus Holding (LNTH)?
What is the market cap of Lantheus Holding (LNTH)?
